NUVB insider transaction filings
Nuvation Bio Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen NUVB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Hattersley Gary — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 100,000 @ $1.87 · Sale (S): 100,000 @ $7.09 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | Sauvage Philippe — Chief Financial Officer | Option exercise (M): 39,999 @ $2.17 · Option exercise (M): 1 @ $1.97 · Option exercise (M): 39,999 (derivative) @ $0 · Option exercise (M): 1 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Sauvage Philippe — Chief Financial Officer | Option exercise (M): 47,668 @ $2.17 · Sale (S): 47,668 @ $6.01 · Option exercise (M): 47,668 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Markel Stacy — CHIEF PEOPLE OFFICER | Option exercise (M): 90,380 @ $1.87 · Option exercise (M): 34,620 @ $1.74 · Sale (S): 125,000 @ $6.03 · Option exercise (M): 90,380 (derivative) @ $0 · Option exercise (M): 34,620 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Wentworth Kerry — CHIEF REGULATORY OFFICER | Option exercise (M): 63,000 @ $2.93 · Sale (S): 63,000 @ $6.02 · Option exercise (M): 63,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Mashal Robert — Director | Purchase (P): 25,000 @ $4.73 | EDGAR |
| 2026-05-26 | 4 | Mashal Robert — Director | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Bazemore Robert B — Director | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Cui Xiangmin — Director | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4/A | Cui Xiangmin — Director | Grant/award (A): 76,923 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | VERNON W ANTHONY — Director | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | BLICKENSTAFF KIM D — Director | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | FALBERG KATHRYN E — Director | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Option exercise (M): 50,000 @ $1.94 · Sale (S): 50,000 @ $5.02 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Wentworth Kerry — CHIEF REGULATORY OFFICER | Option exercise (M): 36,750 @ $2.93 · Sale (S): 36,750 @ $5.01 · Option exercise (M): 36,750 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Wentworth Kerry — CHIEF REGULATORY OFFICER | Option exercise (M): 100,000 @ $1.87 · Option exercise (M): 100,000 @ $1.94 · Sale (S): 200,000 @ $4.52 · Option exercise (M): 100,000 (derivative) @ $0 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Sauvage Philippe — Chief Financial Officer | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Sjogren Colleen — Chief Commercial Officer | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Makunje Moses — SEE REMARKS | Grant/award (A): 50,761 @ $0 · Grant/award (A): 224,439 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Hanley David C. — CHIEF TECHNICAL OPERATIONS | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Markel Stacy — CHIEF PEOPLE OFFICER | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Hattersley Gary — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Cui Xiangmin — Director | Grant/award (A): 74,813 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Wentworth Kerry — CHIEF REGULATORY OFFICER | Grant/award (A): 748,130 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Hung David — PRESIDENT AND CEO, Director, 10% owner | Grant/award (A): 1,995,012 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Option exercise (M): 150,000 @ $2.93 · Sale (S): 150,000 @ $7.82 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Option exercise (M): 10,000 @ $3.61 · Sale (S): 10,000 @ $7.50 · Option exercise (M): 10,000 @ $3.61 · Sale (S): 10,000 @ $8 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Option exercise (M): 20,000 @ $1.87 · Sale (S): 20,000 @ $7.00 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Hattersley Gary — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 69,051 @ $1.74 · Sale (S): 69,051 @ $7.23 · Option exercise (M): 300,000 @ $1.94 · Sale (S): 300,000 @ $7.23 · Option exercise (M): 69,051 (derivative) @ $0 · Option exercise (M): 300,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Hanley David C. — CHIEF TECHNICAL OPERATIONS | Option exercise (M): 200,000 @ $1.87 · Sale (S): 200,000 @ $7.14 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Option exercise (M): 15,000 @ $1.87 · Sale (S): 15,000 @ $4.76 · Option exercise (M): 15,000 @ $1.87 · Sale (S): 15,000 @ $5.10 · Option exercise (M): 15,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | Hattersley Gary — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 100,000 @ $1.74 · Sale (S): 100,000 @ $5.02 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Mashal Robert — Director | Gift (G): 350,001 (derivative) @ $0 · Gift (G): 350,001 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Sjogren Colleen — Chief Commercial Officer | Purchase (P): 50,000 @ $1.81 | EDGAR |
| 2025-06-18 | 4 | Sauvage Philippe — Chief Financial Officer | Purchase (P): 3,300 @ $1.83 · Purchase (P): 4,000 @ $1.79 | EDGAR |
| 2025-06-18 | 4 | Markel Stacy — CHIEF PEOPLE OFFICER | Purchase (P): 10,000 @ $1.71 | EDGAR |
| 2025-06-18 | 4 | Wentworth Kerry — CHIEF REGULATORY OFFICER | Purchase (P): 26,000 @ $1.79 · Purchase (P): 24,000 @ $1.80 | EDGAR |
| 2025-06-18 | 4 | Hung David — PRESIDENT AND CEO, Director, 10% owner | Purchase (P): 500,000 @ $1.79 | EDGAR |
| 2025-05-23 | 4 | Mashal Robert — Director | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Bazemore Robert B — Director | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | VERNON W ANTHONY — Director | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | BLICKENSTAFF KIM D — Director | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | FALBERG KATHRYN E — Director | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-05-06 | 4 | Liu Dongfang — CHIEF MEDICAL OFFICER | Option exercise (M): 20,000 @ $1.94 · Sale (S): 20,000 @ $2.50 · Option exercise (M): 20,000 (derivative) @ $1.94 | EDGAR |
| 2025-04-08 | 4 | Hung David — PRESIDENT AND CEO, Director, 10% owner | Purchase (P): 200,000 @ $1.66 · Purchase (P): 300,000 @ $1.62 | EDGAR |
| 2025-04-03 | 4 | Mashal Robert — Director | Purchase (P): 1,100 @ $1.67 · Purchase (P): 98,900 @ $1.67 | EDGAR |
| 2025-03-04 | 4 | Sjogren Colleen — Chief Commercial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Sauvage Philippe — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Makunje Moses — SEE REMARKS | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Nuvation Bio Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NUVB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →